Lab in action

Looking to elevate laboratory operations, Yuma Regional’s hospital directors established a leadership model that pairs medical and administrative leaders, resulting in a changed perception of the laboratory’s ability to drive profitability and a $40 million capital investment in laboratory infrastructure.

Situated in a sprawling geographic region in mid-Missouri, Boone Health expanded its reach to improve access to high-quality holistic care throughout the area, improving the health of community members and increasing net revenue along the way.

Prevented from providing testing services to its community members due to a non-compete agreement with a national laboratory, Kootenai Health laboratory leaders deepened their relationship with Mayo Clinic Laboratories, receiving tactical support and guidance to launch an in-house reference lab just days after the non-compete agreement expired.

Faced with a population increase and the need to expand both laboratory testing capacity and capabilities, Yuma Regional Medical Center leaned into its relationship with Mayo Clinic Laboratories to gain insights to strengthen community ties, attract new providers, and positively impact patient outcomes.

By collaborating with Mayo Clinic Laboratories, Morris Hospital & Healthcare Center has been able to expand complex and specialized lab testing in the communities they serve.

Partnering with Mayo Clinic has helped St. Clair Health improve patient care and gain a new competitive advantage in pharmacogenetics.

In recent articles, Mayo Clinic Laboratories emphasizes the transformative potential of recognizing and leveraging the capabilities of a hospital laboratory. With more touchpoints than any other outpatient service line, the laboratory is full of opportunity to enhance local healthcare delivery and bolster a hospital’s financial stability.

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his latest article, he describes the untapped potential of hospital laboratories and how health systems can maximize the value of their labs.

Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins “Becker’s Healthcare Podcast” to discuss organizational alignment during times of change. She shares her expertise on creating transparency, fostering open communication, and using data to stay on track with business goals.

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his first article, Dr. Morice reflects on the diagnostic landscape and predicts trends that could influence the market in 2024.

In a quiet suburb outside of Minneapolis, Minnesota, an ordinary Saturday took a sudden and alarming turn for Scott Olson when he began experiencing symptoms of ventricular tachycardia. Central to the care and treatment he'd receive at Mayo Clinic was the precise testing that was done by Mayo's Cardiac Pathology Lab, which uncovered the true cause of his erratic heart rhythm. That discovery not only clarified Scott's diagnosis, but also highlighted the critical role that advanced diagnostics plays in guiding successful patient outcomes.

Central nervous system infections, such as meningitis and encephalitis, can be devastating for affected patients. While specific treatments are available for some of these infections, it first requires identifying the precise cause of infection. To meet that need, Mayo Clinic Laboratories has developed a metagenomics assay that can identify more than 1,000 pathogenic organisms in cerebrospinal fluid. The innovative assay, which uses an approach known as shotgun metagenomic sequencing, is one of the only such tests currently available.

What started as a persistent headache for Spencer Lodin soon devolved into slowed speech, seizures, and hallucinations, symptoms which stumped ER doctors into thinking he had meningitis or was suffering from psychosis. Finally, specialized testing at Mayo Clinic identified Spencer's condition as GFAP-IgG associated autoimmune encephalitis, which allowed for targeted treatment and a full recovery.

Mayo Clinic Laboratories introduces the Inherited Parkinson’s Disease Gene Panel (Mayo ID: PARDP), a collaborative breakthrough poised to transform Parkinson’s disease diagnosis and treatment. Led by Rodolfo Savica, M.D., Ph.D., and Zhiyv (Neal) Niu, Ph.D., this comprehensive test offers unparalleled insights into Parkinson’s genetics, unveiling novel gene associations and enhancing diagnostic precision through next-generation sequencing. The panel’s capabilities include detecting subtle genetic variations and identifying familial patterns, promising personalized medicine advancements.

Since 1992, cases of colorectal cancer have been on a slow decline, yet 52,550 people died from it in 2023. At Mayo Clinic, a cutting-edge menu of both germline (inherited genetic alterations) and somatic (tumors due to non-inherited genetic alterations) testing are two critical tools helping to improve targeted treatments for colorectal and other common gastrointestinal cancers.

Dr. Linda Hasadsri’s firsthand encounter with the genetic tests she’s helped develop has provided rare insight into testing quality and implications, enhancing their ability to advocate for the value of testing and infusing their work with deep empathy.